Show simple item record

dc.contributor.authorPrice, Patricia
dc.contributor.authorLee, Silvia
dc.contributor.authorAffandi, Jacquita
dc.contributor.authorParsons, Richard
dc.contributor.authorNaylor, L.
dc.contributor.authorWatts, G.
dc.contributor.authorIrish, A.
dc.date.accessioned2017-01-30T14:03:33Z
dc.date.available2017-01-30T14:03:33Z
dc.date.created2016-12-06T19:30:20Z
dc.date.issued2017
dc.identifier.citationPrice, P. and Lee, S. and Affandi, J. and Parsons, R. and Naylor, L. and Watts, G. and Irish, A. 2017. Cytomegalovirus antibody and vascular pathology in renal transplant recipients. Journal of Medical Virology. 89 (1): pp. 177-181.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/37480
dc.identifier.doi10.1002/jmv.24602
dc.description.abstract

Cytomegalovirus (CMV) has been linked with vascular pathology and is a common complication of renal transplantation. We addressed whether CMV seropositivity influences vascular pathology several years after transplant. Levels of CMV antibody increased with age, were higher in transplant recipients than healthy controls (P < 0.001), and correlated with vascular endothelial function measured by flow mediated-dilation of the brachial artery (FMD). However, the optimal general linear model predicting FMD included CMV seropositivity as a marginal effect (P = 0.068), with age (P = 0.013), gender (P < 0.0001), and transplantation (P < 0.0001). Other measures of the burden of CMV are being tested as CMV prophylaxis is feasible as an approach to reduce vascular disease.

dc.publisherWILEY-LISS
dc.titleCytomegalovirus antibody and vascular pathology in renal transplant recipients
dc.typeJournal Article
dcterms.source.volume89
dcterms.source.number1
dcterms.source.startPage177
dcterms.source.endPage181
dcterms.source.issn0146-6615
dcterms.source.titleJournal of Medical Virology
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusOpen access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record